Abstracts tagged "Animal Model"

Abstract Number: 0934 • ACR Convergence 2025
The Use Of Preclinical Models To Understand Drivers Of Lupus Pathogenesis
Arielle Glatman Zaretsky¹, Carley Tasker¹, Pablo Abreu¹, Ciara Torres², Li-Hong Ben¹, Scott MacDonnell¹, Andre Limnander¹ and Jamie Orengo¹, ¹Regeneron, Tarrytown, NY, ²Regeneron, Tarrytown
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease with a prevalence of 1.4-15.13/100,000 adults globally. SLE is highly heterogenous and can involve…
Abstract Number: 0052 • ACR Convergence 2025
Profiling of MT-3534, a Humanized Monoclonal Antibody Targeting Peptidylarginine Deiminase 4, as a Candidate Drug for the Treatment of RA
Hisae Niki¹, Akitoshi Nishizawa², Yuuichi Ono¹, Makoto Yamazaki¹, Satoshi Takanashi³, Keiko Yoshimoto⁴, Mitsuhiro Akiyama³, Tsutomu Takeuchi⁵ and Yuko Kaneko⁴, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ²Mitsubishi Tanabe Pharma Corporation, Fujisawa, Kanagawa, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁵Saitama Medical University and Keio University, Tokyo, Japan
Background/Purpose: Although the management of rheumatoid arthritis (RA) has been remarkably improved, there are still patients who have not responded to existing targeted drugs that…
Abstract Number: 1003 • ACR Convergence 2025
Potent Engineering of Polyfunctional CD8+ T Cells by a Novel In Vivo CAR mRNA Product Candidate (CPTX2309) in a Targeted Lipid Nanoparticle (tLNP) Utilizing CellSeekerTM Technology
Yan Zhang¹, Brittany Ross¹, Aditi Upadhye¹, Diana Galvan¹, Shaun E Grosskurth¹, Yanjie Bao¹, Romina Riener¹, Annabel Wang¹, Aric Frantz¹, Gregor B Adams¹, Michael Rosenzweig¹, Ramin Farzaneh-Far¹, Priya Karmali¹, Adrian I Bot¹, Carl June² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: A major objective in autoimmunity is immune reset, requiring autoreactive B cell depletion in tissues. We designed an in vivo CAR product candidate (CPTX2309)…
Abstract Number: 0935 • ACR Convergence 2025
Oral Antibiotic Treatment Reduces Anxiety in a Murine Model of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Cecilia Stumpf¹, Brianna Thompson², Vanessa Manada De Lobos² and Carla Marie Cuda³, ¹Northwestern University, Elmhurst, IL, ²Northwestern University, Chicago, ³Northwestern University, Chicago, IL
Background/Purpose: Unclear mechanisms underlying diffuse NPSLE (anxiety, cognitive dysfunction) lead to the devastating impact of this disease on patients’ health-related quality-of-life. Dysbiosis of gut microbiota…
Abstract Number: 0050 • ACR Convergence 2025
TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
Preeyam Patel¹, Matthew Siegel², Emily Lewis³, David Giles³, Justin LaFountaine³, Joshua Friedman³ and Andy Spencer³, ¹Spyre Therapeutics, Waltham, ²Spyre Therapeutics, Menlo Park, CA, ³Spyre Therapeutics, Waltham, MA
Background/Purpose: The development of disease-modifying anti-rheumatic drugs (DMARDs) has reduced disease activity in patients living with rheumatic diseases. Despite this, there is continued unmet need…
Abstract Number: 0094 • ACR Convergence 2024
Small GTPase Rab4A Regulates Mouse Behavior Through Altered Serum Serotonin Levels and Microglial mTORC1 Activation in Lupus-prone B6.TC Mice
Thomas Winans¹, Xiaojing Wang², Joshua Lewis², Jessica Nolan¹, Laurence Morel³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, ²SUNY Upstate Medical University, Syracuse, NY, ³University of Texas health San Antonio, San Antonio, TX, ⁴SUNY, Syracuse, NY
Background/Purpose: Rab4A is a small GTPase that is overexpressed in patients and mice with systemic lupus erythematosus (SLE, PubMed ID: 23897774; PubMed ID 31805010). Rab4A…
Abstract Number: 0964 • ACR Convergence 2024
Engaging the PD-1 Pathway Attenuates Inflammation Associated Fibrosis in Systemic Sclerosis Fibroblasts and a Preclinical Mouse Model
Maithri Aspari¹, Voon Ong², Klaus Soendergaard³, Esben Naeser⁴, Malene Hvid⁴, Angela Tam⁵, Shiwen Xu⁵, Christopher Denton⁶, David Abraham⁷, Bent Deleuran¹ and Stinne Greisen⁸, ¹Aarhus University, Aarhus, Denmark, ²University College London, London, England, United Kingdom, ³Aarhus University Hospital, Aarhus, Denmark, ⁴AARHUS UNIVERSITET, AARHUS C, Denmark, ⁵University College London, London, United Kingdom, ⁶University College London, Northwood, United Kingdom, ⁷UCL, London, United Kingdom, ⁸Aarhus University/Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: The precise molecular mechanisms driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) remain to be elucidated. The immune regulatory programmed cell death protein 1…
Abstract Number: 0097 • ACR Convergence 2024
The Human Lupus TREX1 D18N Mutation Engineered in C. Elegans Leads to Cell Death. What Can We Learn About Lupus Using C. Elegans?
Htay Htay Kyi¹, Patricia Barreto², Yeshaswi Pulijala³, Thejasvi Venkatachalam³ and Martha Soto², ¹Rutgers New Jersey Medical School, Jersey City, NJ, ²Robert Wood Johnson Medical School, Piscataway, NJ, ³RWJ-PATHOLOGY-RESEARCH-PISC, Piscataway
Background/Purpose: TREX1 gene encodes the three prime repair exonuclease 1 enzyme that degrades DNA. TREX1 plays a key role in genomic DNA degradation, cell death…
Abstract Number: 0971 • ACR Convergence 2024
Ligand-Receptor Analysis Reveals Myeloid-Mediated Pro-Inflammatory Responses and Loss of Mesenchymal Signaling Driven by TNFR1 in Experimental Pulmonary Hypertension
Gaochan Wang¹, Stacey Duemmel² and Benjamin Korman³, ¹University of Rochester School of Medicine and Dentistry, Rochester, NY, ²URMC, UNIVERSITY OF ROCHESTER, Rochester, NY, ³University of Rochester, Rochester, NY
Background/Purpose: Pulmonary hypertension (PH) is a severe, progressive disorder characterized by elevated pulmonary artery pressures, right ventricular hypertrophy, and increased mortality which is a severe…
Abstract Number: 0281 • ACR Convergence 2024
Intra-articular Treatment Combining Sustained Release Colchicine Encapsulated in Microspheres, and Ropivacaine, Is Effective in Inflammatory Arthritis in Rats
Julien GRASSOT¹, Farah MARZOUKI², Roxane HERVE³, Magali BECKLER⁴, Luca SEMERANO⁵, Natacha BESSIS⁶, Elodie RIVIERE⁷, Charles SANSON², Gauthier POULIQUEN², Philippe POULETTY⁸ and Marie-Christophe BOISSIER⁹, ¹PK MED, LYON, Rhone-Alpes, France, ²PK MED, LYON, France, ³INSERM U1125, Bobigny, France, ⁴INSERM 1125, Bobigny, France, ⁵Avicenne Teaching Hospital APHP, Bobigny, France, ⁶INSERM, Université Sorbonne Paris Nord, PARIS, France, ⁷INSERM, Université Sorbonne Paris Nord, APHP, PARIS, France, ⁸PK MED, PARIS, France, ⁹University Sorbonne Paris Nord, Bobigny, France
Background/Purpose: Gout is a common disease with a prevalence and incidence on the rise worldwide. However, approved treatments to treat acute gout flares have slow…
Abstract Number: 1430 • ACR Convergence 2024
C57BL/6.NOD-Aec1Aec2 Mice Recapitulate Sjögren’s Serology Better Than NOD.B10Sn-H2b Models and JAK Inhibitor Treatment Improves Immunoglobulins and Salivary Gland Inflammation but Not Salivary Flow in Sjögren’s Mice
Sara McCoy¹ and Ilya Gurevic², ¹University of Wisconsin, Middleton, WI, ²University of Wisconsin, Madison
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease in which interferons (IFNs) are believed to play a major role/ JAK inhibitors (JAKinibs) block IFN…
Abstract Number: 0320 • ACR Convergence 2024
Comparative Transcriptional Profiling Reveals Shared Pathway Activation Between Human Jo-1+ Anti-Synthetase Syndrome and Murine Histidyl-tRNA Synthetase-Induced Myositis
Iago Pinal-Fernandez¹, Daniel Reay², Timothy Oriss², katherine Pak³, Maria Casal-Dominguez⁴, jose milisenda⁵, Albert Selva-O’Callaghan⁶, Werner Stenzel⁷, Andrew Mammen¹ and Dana Ascherman⁸, ¹NIH, Bethesda, MD, ²University of Pittsburgh School of Medicine, Pittsburgh, PA, ³National Institutes of Health, Bethesda, MD, ⁴NIH, Bathesda, MD, ⁵Hospital Clinic de Barcelona, Barcelona, Spain, ⁶Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁷Charite University, Berlin, Germany, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Previous work has shown unique gene expression profiles in muscle tissue corresponding to the anti-synthetase syndrome, with an emphasis on interferon gene signatures (Type…
Abstract Number: 1776 • ACR Convergence 2024
Animal Models of Pediatric MOGAD
Yike Jiang¹, Elliot Lin², Estefany Reyes², Devon DiPalma², Sundar Khadka², Heather Van Mater² and Mari Shinohara², ¹Duke Univerisity, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a devastating demyelinating disease that disproportionally affects children. Discovered in 2018, MOGAD is now internationally recognized as…
Abstract Number: 0785 • ACR Convergence 2024
Exploring the Link Between Atgl-Dependent Lipolysis and Dermal Fibrosis in Systemic Sclerosis
Elizabeth Caves¹, Agrani Dixit¹, Anna Jussila², Vivian Lei³, Hailey Edelman⁴, Muhammad Hamdan⁵, Ian Odell⁵, Monique Hinchcliff⁶, Radhika Atit⁷ and Valerie Horsley¹, ¹Yale School of Medicine, New Haven, CT, ²Stanford Medicine, Stanford, CA, ³University of North Carolina School of Medicine, Chapel Hill, ⁴Vanderbilt School of Engineering, New Haven, ⁵Yale School of Medicine, New Haven, ⁶Yale School of Medicine, Westport, CT, ⁷Case Western Reserve University College of Arts and Sciences, Cleveland
Background/Purpose: Resident lipid-filled dermal adipocytes are depleted in both systemic sclerosis (SSc) and scleroderma mouse models, but mechanisms are poorly understood. We undertook studies in mouse…
Abstract Number: 1838 • ACR Convergence 2024
M5542: A Potent CD80, CD86, and OX40L Antagonist Fusion Molecule for the Treatment of Autoimmune Diseases
Michelle Downing¹, Ling Zhang¹, Aditee Desphpande¹, Hong Zhang¹, Ohad Tarcic², Mira toister-achituv², Alec Gross³, Gang Chen³ and Chia Chi Sun¹, ¹EMD Serono Research and Development Institute, Inc., Billerica, MA, ²Inter-lab Ltd, Merck KGaA, Yavne, Israel, ³EMD Serono Reserch and Development Institute, Inc, Billerica, MA
Background/Purpose: Overactive adaptive immune responses contribute to many autoimmune diseases such as systemic lupus erythematosus (SLE). Chronically activated autoreactive T-effector cells play a pivotal role…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].